Axsome Therapeutics - AXSM Stock Forecast, Price & News

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Mizuho lowered their price target on shares of Axsome Therapeutics from $51.00 to $49.00 in a report on Tuesday, May 3rd. Morgan Stanley lifted their price target on Axsome Therapeutics from $54.00 to $55.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 10th. Cowen upped their price objective on Axsome Therapeutics from $120.00 to $130.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 29th. Cantor Fitzgerald cut their target price on shares of Axsome Therapeutics from $64.00 to $54.00 in a report on Wednesday, August 10th. Finally, Cowen increased their price target on shares of Axsome Therapeutics from $120.00 to $130.00 and gave the stock an "outperform" rating in a report on Wednesday, June 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $90.63.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $43.13 on Thursday. The company has a debt-to-equity ratio of 6.15, a quick ratio of 2.20 and a current ratio of 2.44. The firm has a fifty day moving average of $37.32 and a 200 day moving average of $34.04. The firm has a market cap of $1.68 billion, a PE ratio of -11.00 and a beta of 1.92. Axsome Therapeutics has a one year low of $19.38 and a one year high of $48.82.

Axsome Therapeutics (NASDAQ:AXSM - Get Rating) last released its earnings results on Tuesday, August 9th. The company reported ($1.06) EPS for the quarter, topping analysts' consensus estimates of ($1.19) by $0.13. During the same quarter in the previous year, the firm posted ($0.86) EPS. As a group, research analysts predict that Axsome Therapeutics will post -4.22 EPS for the current fiscal year.